Insider Selling: CryoPort (NASDAQ:CYRX) Insider Sells $486,192.00 in Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Edward Zecchini sold 33,600 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the transaction, the insider owned 109,719 shares in the company, valued at approximately $1,587,633.93. This trade represents a 23.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

CryoPort Price Performance

CYRX opened at $14.62 on Monday. The business has a fifty day simple moving average of $12.42 and a 200 day simple moving average of $10.34. The company has a market capitalization of $736.85 million, a PE ratio of 10.83 and a beta of 1.90. CryoPort, Inc. has a 1 year low of $6.16 and a 1 year high of $16.73.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The firm had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. Equities analysts anticipate that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CryoPort

Several hedge funds have recently bought and sold shares of CYRX. Basepoint Wealth LLC bought a new stake in shares of CryoPort during the 4th quarter worth approximately $34,000. Tower Research Capital LLC TRC increased its stake in CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after acquiring an additional 4,375 shares during the last quarter. AlphaQuest LLC acquired a new position in CryoPort during the third quarter valued at approximately $79,000. Quadrature Capital Ltd acquired a new position in CryoPort during the fourth quarter valued at approximately $97,000. Finally, Corient Private Wealth LLC bought a new stake in CryoPort during the fourth quarter worth $113,000. 92.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on CYRX shares. Guggenheim lifted their price objective on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Craig Hallum raised their target price on shares of CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. BTIG Research lifted their price target on shares of CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. KeyCorp boosted their price target on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Finally, Jefferies Financial Group set a $13.50 price target on CryoPort in a research report on Monday, June 8th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, CryoPort has an average rating of “Moderate Buy” and an average target price of $15.11.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.